Targeted overexpression of the human urotensin receptor transgene in smooth muscle cells: Effect of UT antagonism in ApoE knockout mice fed with Western diet

Atherosclerosis

Volumn 204, Issue 2, 2009, Pages 395-404

  Papadopoulos, Panayiota ^a   Bousette, Nicolas ^a   Al Ramli, Wisam ^a   You, Zhipeng ^a   Behm, David J ^b   Ohlstein, Eliot H ^b   Harrison, Stephen M ^c   Douglas, Stephen A ^b   Giaid, Adel ^a  

^a MONTREAL GENERAL HOSPITAL   (Canada)

^b GLAXOSMITHKLINE   (United States)

^c GLAXOSMITHKLINE   (United Kingdom)

Author keywords

Atherosclerosis; Hyperlipidemia; Immuohistochemistry; Knockout mice; Transgenic mice; Western blotting

Indexed keywords

[2,6 DICHLORO N [4CHLORO 3 [[2 (DIMETHYLAMINO)ETHYL]OXY]PHENYL] 4 [TRIFLUOROMETHYL BENZENESULFONAMIDE]; SB 657510A; SULFONAMIDE; UNCLASSIFIED DRUG; UROTENSIN; UROTENSIN II;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATHEROSCLEROSIS; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFECT; IMMUNOHISTOCHEMISTRY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SMOOTH MUSCLE FIBER; UPREGULATION;

ACETYL-COA C-ACETYLTRANSFERASE; ANIMALS; AORTA; AORTIC DISEASES; APOLIPOPROTEINS E; ATHEROSCLEROSIS; BLOTTING, WESTERN; CARDIOVASCULAR AGENTS; CHOLESTEROL, DIETARY; DISEASE MODELS, ANIMAL; FOAM CELLS; HUMANS; IMMUNOHISTOCHEMISTRY; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICE, TRANSGENIC; MICROFILAMENT PROTEINS; MUSCLE PROTEINS; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, SMOOTH MUSCLE; PROMOTER REGIONS, GENETIC; RECEPTORS, G-PROTEIN-COUPLED; SULFONAMIDES; TRIGLYCERIDES; UROTENSINS;

EID: 67349124097     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2008.10.044     Document Type: Article

References (33)

1. Ames R.S., Sarau H.M., Chambers J.K., et al. Human urotensin-II is a potent vasoconstrictor and agonist for the orphan receptor GPR14. Nature 401 6750 (1999) 282-286
2. Douglas S.A., Sulpizio A.C., Piercy V., et al. Differential vasoconstrictor activity of human urotensin-II in vascular tissue isolated from the rat, mouse, dog, pig, marmoset and cynomolgus monkey. Br J Pharmacol 131 7 (2000) 1262-1274
3. Thanassoulis G., Huyhn T., and Giaid A. Urotensin II and cardiovascular diseases. Peptides 25 10 (2004) 1789-1794
4. Tolle M., and vad der Geit M. Cardiorenovascular effects of urotensin II and the relevance of the UT receptor. Peptides 29 5 (2008) 743-763
5. Watanabe T., Pakala R., Katagiri T., and Benedict C.R. Synergistic effect of urotensin II with mildly oxidized LDL on DNA synthesis in vascular smooth muscle cells. Circulation 104 1 (2001) 16-18
6. Watanabe T., Pakala R., Katagiri T., and Benedict C.R. Synergistic effect of urotensin II with serotonin on vascular smooth muscle cell proliferation. J Hypertens 19 12 (2001) 2191-2196
7. Watanabe T., Takahashi K., Kanome T., et al. Human urotensin-II potentiates the mitogenic effect of mildly oxidized low-density lipoprotein on vascular smooth muscle cells: comparison with other vasoactive agents and hydrogen peroxide. Hypertens Res 29 10 (2006) 821-831
8. Sauzeau V., Le Mellionnec E., Bertoglio J., Scalbert E., Pacaud P., and Loirand G. Human urotensin II-induced contraction and arterial smooth muscle cell proliferation are mediated by RhoA and Rho-kinase. Circ Res 88 11 (2001) 1102-1104
9. Watanabe T., Suguro T., Kanome T., et al. Urotensin II accelerates foam cell formation in human monocytes-derived macrophages. Hypertension 46 4 (2005) 738-744
10. Sheridan M.A., Plisetskaya E.M., Bern H.A., and Gorbman A. Effects of somatostatin-25 and urotensin II on lipid and carbohydrate metabolism of coho salmon, Oncorhynchus kisutch. Gen Comp Endocrinol 66 3 (1987) 405-414
11. Segain J.P., Rolli-Derkinderen M., Gervois N., Raingeard de la Bletiere D., Loirand G., and Pacaud P. Urotensin II a new chemotactic factor for UT receptor-expressing monocytes. J Immunol 179 2 (2007) 901-909
12. Djordjevic T., BelAiba R.S., Bonello S., Pfeilschifter J., Hess J., and Gorlach A. Human urotensin II is a novel activator of NADPH oxidase in human pulmonary artery smooth muscle cells. Arterioscler Thromb Vasc Biol 25 3 (2005) 519-525
13. Bousette N., Patel L., Douglas S.A., Ohlstein E.H., and Giaid A. Increased expression of urotensin II and its cognate receptor GPR14 in atherosclerotic lesions of the human aorta. Atherosclerosis 176 1 (2004) 117-123
14. Hassan G.S., Douglas S.A., Ohlstein E.H., and Giaid A. Expression of urotensin-II in human coronary atherosclerosis. Peptides 26 12 (2005) 2464-2472
15. Maguire J.J., Kuc R.E., Wiley K.E., Kleinz M.J., and Davenport A.P. Cellular distribution of immunoreactive urotensin-II in human tissues with evidence of increased expression in atherosclerosis and a greater constrictor response of small compared to large coronary arteries. Peptides 25 10 (2004) 1767-1774
16. Wang Z.J., Shi L.B., Xiong Z.W., et al. Alteration of vascular urotensin II receptor in mice with apolipoprotein E gene knockout. Peptides 27 4 (2006) 858-863
17. Li L., Miano J.M., Mercer B., and Olson E.N. Expression of the SM22alpha promoter in transgenic mice provides evidence for distinct transcriptional regulatory programs in vascular and visceral smooth muscle cells. J Cell Biol 132 5 (1996) 849-859
18. Kuhlencordt P.J., Gyurko R., Han F., et al. Accelerated atherosclerosis, aortic aneurysm formation, and ischemic heart disease in apolipoprotein E/endothelial nitric oxide synthase double-knockout mice. Circulation 104 4 (2001) 448-454
19. Douglas S.A., Behm D.J., Aiyar N.V., et al. Nonpeptidic urotensin-II receptor antagonists I: in vitro pharmacological characterization of SB-706375. Br J Pharmacol 145 (2005) 620-635
20. Giaid A., Yanagisawa M., Langleben D., et al. Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N Engl J Med 328 24 (1993) 1732-1739
21. Douglas S.A., Tayara L., Ohlstein E.H., Halawa N., and Giaid A. Congestive heart failure and expression of myocardial urotensin II. Lancet 359 9322 (2002) 1990-1997
22. Bousette N., Pottinger J., Ramli W., et al. Urotensin-II receptor blockade with SB-611812 attenuates cardiac remodeling in experimental ischemic heart disease. Peptides 27 11 (2006) 2919-2926
23. Saito T., Hu F., Tayara L., Fahas L., Shennib H., and Giaid A. Inhibition of NOS II prevents cardiac dysfunction in myocardial infarction and congestive heart failure. Am J Physiol Heart Circ Physiol 283 1 (2002) H339-H345
24. Heringlake M., Kox T., Uzun O., et al. The relationship between urotensin II plasma immunoreactivity and left ventricular filling pressures in coronary artery disease. Regul Pept 121 1-3 (2004) 129-136
25. Suguro T., Watanabe T., Ban Y., et al. Increased human urotensin II levels are correlated with carotid atherosclerosis in essential hypertension. Am J Hypertens 20 2 (2007) 211-217
26. Maguire J.J., Kuc R.E., Wiley K.E., Kleinz M.J., and Davenport A.P. Cellular distribution of immunoreactive urotensin-II in human tissues with evidence of increased expression in atherosclerosis and a greater constrictor response of small compared to large coronary arteries. Peptide 25 (2004) 1767-1774
27. Katugampola S.D., Kuc R.E., Maguire J.J., and Davenport A.P. G-protein-coupled receptors in human atherosclerosis: comparison of vasoconstrictors (endothelin and thromboxane) with recently de-orphanized (urotensin-II, apelin and ghrelin) receptors. Clin Sci (Lond) 103 Suppl. 48 (2002) 171S-175S
28. Lescot E., Bureau R., and Rault S. Nonpeptide Urotensin-II receptor agonists and antagonists: review and structure-activity relationships. Peptides 29 5 (2008) 680-690
29. Dhanak D., Neeb M.J., and Douglas S.A. Urotensin-II receptor modulators. Annu Rep Med Chem 38 (2003) 99-110
30. Sidharta P.N., Wagner F.D., Bohnemeier H., et al. Pharmacodynamics and pharmacokinetics of the urotensin II receptor antagonist palosuran in microalbuminuric, diabetic patients. Clin Pharmacol Ther 80 3 (2006) 246-256
31. Ong K.L., Wong L.Y., and Cheung B.M. The role of urotensin II in the metabolic syndrome. Peptides 29 5 (2008) 859-867
32. Rakowski E., Hassan G.S., Dhanak D., Ohlstein E.H., Douglas S.A., and Giaid A. A role for urotensin II in restenosis following balloon angioplasty: use of a selective UT receptor blocker. J Moll Cell Cardiol 39 5 (2005) 785-791
33. Bousette N., Hu F., Ohlstein E.H., Dhanak D., Douglas S.A., and Giaid A. Urotensin-II blockade with SB-611812 attenuates cardiac dysfunction in a rat model of coronary artery ligation. J Mol Cell Cardiol 41 2 (2006) 285-295